Go Pro
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
OTCMKTS:PURE

PURE Bioscience Q4 2024 Earnings Report

PURE Bioscience logo
$0.07 +0.01 (+12.18%)
As of 09/25/2026 09:30 AM Eastern
ProfileEarnings History

PURE Bioscience EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PURE Bioscience Revenue Results

Actual Revenue
$0.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PURE Bioscience Announcement Details

Quarter
Q4 2024
Date
10/29/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PURE Bioscience Earnings Headlines

PURE Bioscience (OTCMKTS:PURE) Shares Break Above Two Hundred Day Moving Average - Here's Why
September 26 at 2:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31051824
PURE Bioscience (OTCMKTS:PURE) Stock Passes Above 200-Day Moving Average - Here's What Happened
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029803
October 7th dollar deadline
Former hedge fund manager Larry Benedict called the 2020 market drop and the 2022 downturn before they happened. Now he's pointing to October 7 as a critical date for the US dollar. He says a federal deadline on that day could hit some of the biggest AI stock winners, with gains potentially cut by as much as 40 percent. Benedict is hosting a free briefing to walk through a three-step approach he believes could help investors prepare.tc pixel
September 26 at 1:00 AM  |  Brownstone Research (Ad)
Pure Bioscience Inc.
August 12, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/pure/financials
PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results
June 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260615772156/en/pure-bioscience-reports-fiscal-third-quarter-2026-financial-results/
Purecore Strengthens Technical Advisory Expertise with Nuclear Fuel Cycle and Uranium Enrichment Specialist, Ted Rygas, PhD
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311870/0/en/purecore-strengthens-technical-advisory-expertise-with-nuclear-fuel-cycle-and-uranium-enrichment-specialist-ted-rygas-phd.html
See More PURE Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PURE Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PURE Bioscience and other key companies, straight to your email.

About PURE Bioscience

PURE Bioscience (OTCMKTS:PURE), Inc. develops and commercializes antimicrobial products based on its proprietary silver dihydrogen citrate (SDC) technology. The company’s formulations are designed to provide broad-spectrum antimicrobial activity while supporting applications where effective sanitation and surface treatment are required.

Its product portfolio has included disinfectants, sanitizers and antimicrobial solutions for hard-surface cleaning, food processing, healthcare, hospitality, institutional and commercial environments. PURE Bioscience has also offered products intended for use in food-safety and odor-control applications, with formulations and uses subject to applicable regulatory approvals.

The company markets its products primarily through business, industrial and institutional channels, including distributors and other commercial partners. PURE Bioscience is based in San Diego, California. Publicly available information about its current leadership and geographic operating footprint is limited, so no further management details are provided here.

View PURE Bioscience Profile
Earnings Tools